|
|
非唑奈坦市场分析报告
|
FEZOLINETANT (ESN364) - Emerging Insight and Market Forecast - 2030
... symptoms. It is being developed by Astellas. Fezolinetant (ESN364) is a proprietary, oral, ... and access to available databases. FEZOLINETANT (ESN364) Analytical Perspective by ... DelveInsight In-depth FEZOLINETANT (ESN364) Market Assessment This ...
Global Vasomotor Symptoms of Menopause Treatment Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery
... to 2025 is primarily split into: Estetrol Fezolinetant FP-101 HBN-2 Others In Chapter 7, on the ...
Global Vasomotor Symptoms of Menopause Treatment Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries
... covered in this report are: Estetrol Fezolinetant FP-101 HBN-2 Others Most widely ...
Global Vasomotor Symptoms of Menopause Treatment Industry Research Report, Competitive Landscape, Market Size, Regional Status and Prospect
... to 2027 is primarily split into: Estetrol Fezolinetant FP-101 HBN-2 Others In Chapter 6 and ...
COVID-19 Outbreak-Global Vasomotor Symptoms of Menopause Treatment Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020
... to 2025 is primarily split into: Estetrol Fezolinetant FP-101 HBN-2 Others In Chapter 5 and ...
2020-2025 Global Vasomotor Symptoms of Menopause Treatment Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
... to 2025 is primarily split into: Estetrol Fezolinetant FP-101 HBN-2 Others In Chapter 7, on the ...
2015-2027 Global Vasomotor Symptoms of Menopause Treatment Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region
... , Inc. Major Types Covered Estetrol Fezolinetant FP-101 HBN-2 Others Major Applications ...
Global Vasomotor Symptoms of Menopause Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028
... . Market segment by Type, covers Estetrol Fezolinetant FP-101 HBN-2 Others Market segment ...
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2018, provides an ...
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017
Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H2 2017, provides an ...
Vasomotor Symptoms of Menopause Treatment Market, Global Outlook and Forecast 2022-2028
... Segment Percentages, by Type, 2021 (%) Estetrol Fezolinetant FP-101 HBN-2 Others Global Vasomotor ...
Global Menopausal Hot Flashes Market Size study & Forecast, by Treatment Type (Hormonal Treatment and Non-hormonal Treatment) and Regional Analysis, 2022-2029
... a new drug application (NDA) for fezolinetant from Astellas Pharma Inc. in June ... , the experimental oral, nonhormonal chemical fezolinetant is appealing for approval. In order to increase ...
Non Hormonal Contraceptives Market for Women’s Health by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030
The non hormonal contraceptives market is expected to reach USD 1.8 billion in 2021 and anticipated to grow at a CAGR of 22% during the forecast period 2021-2030. According to the World Health Organization (WHO), around one-third of clinical conditions ...
Uterine Fibroids - Pipeline Insight, 2021
... (KLH-2109) Telapristone Acetate Vilaprisan Fezolinetant CTX 030916
Vasomotor Symptoms - Pipeline Insight, 2021
... Osanetant Q-122 Elinzanetant Acolbifene + prasterone Fezolinetant Elismetrep Filgrastim
Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (NA, Europe, APAC, Latin America, MEA), And Segment Forecasts, 2025 - 2030
... menopause. This prescription drug, called fezolinetant, is specifically designed for those who ...
Vasomotor Symptoms of Menopause Treatment Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Application, Product Type
... Homecare Clinic Types Segment: Estetrol Fezolinetant FP-101 HBN-2 Others Companies Covered ...
2023-2028 Global and Regional Vasomotor Symptoms of Menopause Treatment Industry Status and Prospects Professional Market Research Report Standard Version
... , Inc. TherapeuticsMD, Inc. By Types: Estetrol Fezolinetant FP-101 HBN-2 Others By Applications: Hospital ...
Menopausal Hot Flashes Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Type (Oral Liquid v/s Pill), By Treatment Type (Hormonal Treatment, Non-Hormonal Treatment, Alternative Treatment), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Competition, 2020-2030F
... and Drug Administration approved Veozah (fezolinetant), an oral treatment for moderate to severe ...
Global Vasomotor Symptoms of Menopause Treatment Market Research Report 2024(Status and Outlook)
... , Inc. Market Segmentation (by Type) Estetrol Fezolinetant FP-101 HBN-2 Others Market Segmentation ...
|
|
|
|
